Share
The avforums podcast brings you the latest tech, movie and gaming news, plus special features, interviews and show reports from the world of audio visual home entertainment
…
continue reading
Manage episode 521613119 series 3361449
Content provided by Labiotech. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Labiotech or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Daiichi Sankyo has been pioneering ADCs since 2010, with a pipeline targeting over 30 indications and potentially reaching 400,000 patients.
In today’s episode I’m joined by Dr. Markus Kosch, Head of the EU Oncology Business Division at Daiichi Sankyo. A physician by training with a deep academic background in oncology, Markus has spent over two decades advancing cancer care, from clinical practice to leadership roles shaping strategy across Europe and Canada. Since joining Daiichi Sankyo in 2021, he has been at the forefront of one of the industry’s most ambitious ADC pipelines, overseeing more than 60 clinical trials across 24 countries and driving landmark approvals that are redefining treatment in breast, lung, and gastric cancers.
This week's episode is brought to you with the support of Kadans.
Looking for the perfect space to grow your Life Sciences company? Kadans Science Partner is Europe’s leading provider of cutting-edge lab and offices spaces, tailored to your needs. Kadans puts you at the centre of innovation, giving you the chance to connect with top researchers, universities, and investors through its international network. Here, you’ll join a vibrant community of innovators driving real change. Are you ready to take your research to the next level? Learn more at kadans.com – where innovation thrives.
01:45. Meet Markus Kosch
03:12. Clinical background shaping an industry role
04:46. Daiichi Sankyo’s 40-year oncology legacy
06:19. European investments and Munich hub
10:34. ADC platform strengths explained
14:20. Key ESMO 2025 trial data
19:43. Managing risks and partnerships
23:35. Patient advocacy in trial design
33:59. Future of oncology and ADCs
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
Chapters
1. Curing cancer: Daiichi Sankyo's ambitious ADC approach (00:00:00)
2. Meet Markus Kosch (00:01:45)
3. Clinical background shaping an industry role (00:03:12)
4. Daiichi Sankyo’s 40-year oncology legacy (00:04:46)
5. European investments and Munich hub (00:06:19)
6. ADC platform strengths explained (00:10:34)
7. Key ESMO 2025 trial data (00:14:20)
8. Managing risks and partnerships (00:19:43)
9. Patient advocacy in trial design (00:23:35)
10. Future of oncology and ADCs (00:33:59)
175 episodes
))
